Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1998-03-09
2000-05-09
Lilling, Herbert J.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
A01N 6500
Patent
active
060600616
DESCRIPTION:
BRIEF SUMMARY
The subject of the present invention is, in the most general aspect, an extract of at least one plant of the Labiatae family, the said plant being cultured in vitro.
It also relates to a cosmetic or pharmaceutical composition comprising, as active ingredient, at least an effective quantity of such an extract, the use, in a cosmetic composition or for the preparation of a pharmaceutical composition, as active ingredient for controlling disorders involving an inflammatory process or an allergic process, of an effective quantity of at least such an extract and a process of cosmetic treatment involving such an extract.
Later in the text, the expression "Labiatae extract" will have the same meaning as "extract of at least one plant of the Labiatae family".
Inflammation (or an inflammatory process) is a combination of biological reactions which is present in the entire animal kingdom. In man, two diseases out of three exhibit an inflammatory syndrome. The inflammation may be localized. It can be defined as the first response to any local aggression by a series of nonspecific reactions which are triggered regardless of the initial cause and which occur in three phases: vascular, cellulovascular and tissue fibrosis.
Swelling, pain, reddening, and heat are the terms which can be used to describe localized inflammation. These are generally due to infiltration of the injured tissues by an edema and/or vasodilation, that is dilation of the capillaries.
The signs of inflammation may extend to fever, a state of general discomfort and/or an increase in the concentration of certain blood plasma proteins.
It is a phenomena which involves, inter alia, a series of local cellular reactions and the release of cytokines and other mediators such as substance P, the prostaglandins, leukotrienes, bradykinin, histamine or serotonin.
It is also manifested by a modification of blood flow with, at the level of the damaged site, an increase in vascular permeability causing leakage of plasma proteins and of cells into the extracellular fluid, as well as extravasation of leucocytes, mainly neutrophil leucocytes and macrophages towards the inflammatory site.
These phenomena are in fact the result of the action of inflammation mediators.
Among the factors involved in these inflammatory phenomena, there may be mentioned cytokines including in particular interleukin-1.alpha., interleukin-1.beta., interleukin-6, tumor necrosis factors .alpha. and .beta. (TNF-.alpha. and -.beta.), chemokines such as interleukin-8 or monocyte chemotactic and activating factor (MCAF), or other chemotactic factors responsible for the recruitment of lymphocytic, monocytic, Langerhans' or basophilic cells at the level of the inflammatory site such as B-4 leukotrienes or other factors involved in the inflammatory cascade, such as arachidonate acid, prostaglandins, including in particular the E2 prostaglandins.
Inflammatory phenomena are associated with numerous pathologies. There may be mentioned, by way of example, rheumatic conditions such as acute articular rheumatism, rheumatoid arthritis, pulmonary conditions such as emphysema, articular conditions such as arthrosis, tendinitis, periarthritis, spondylarthropathies or articular impairments of chronic enteropathies, allergies, inflammatory phases of alopecia, skin conditions such as sensitive skin, erythemas, in particular due to ultraviolet radiation, pruritus, erythema nodosum, urticaria, systemic mastocytosis, psoriasis, insect bites, other dermatological conditions such as atrophic polychondritis, erythemalgia, necrobiosis lipoidica or disseminated lupus erythematosus.
In the allergic processes, the early factors involved are also cytokines, particularly interleukin-1.alpha. and interleukin-1.beta. and type .alpha. tumor necrosis factor (TNF.alpha.).
Unlike an inflammatory reaction, an allergic reaction is a phenomenon which responds to an external factor or an allergen. It is, in this case, a specifically immunological process which occurs only when an allergen is present and which affects only sensitized su
REFERENCES:
Jain et al "In Vitro Production of essential oil from Proliferating Shoots of Rosmarinus officinalis" Planta Med 57 (1991) pp. 122-124.
Computer Abstract Japan 01102027 Michiko "Production of Antiallergic Drug", Jan. 19, 1989.
Offord et al "Rosemary components inhibit benzo[a]pyrene-induced genotoxicity in human bronchial cells" Carcinogenesis vol. 16, No. 9. pp. 2057-2062 (1995).
Breton Lionel
Martin Richard
Pineau Nathalie
Lilling Herbert J.
Societe l'Oreal S.A.
LandOfFree
Method for preventing or treating disorders involving an inflamm does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing or treating disorders involving an inflamm, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing or treating disorders involving an inflamm will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1062023